The Stellanova Vision
Targeting Cancer-Associated Fibroblasts in the Tumor Microenvironment for Cancer Therapy
Stellanova Therapeutics is developing the first cancer therapies targeting cancer-associated fibroblasts and their symbiotic interactions within the tumor microenvironment.
The discovery and therapeutic targeting of cancer-associated fibroblasts (CAFs), which play integral roles in virtually all hallmarks of cancer including promoting cancer growth and metastasis, lies at the heart of Stellanova’s science and mission. Our discovery platform integrates advanced computational biology, including single cell analyses, sophisticated cell biological functional assays enabled genetic engineering, and a state-of-the-art antibody discovery and development platform. Our lead candidate is an antibody targeting the factor DKK3 which functions to promote cancer cell therapeutic resistance, metastases, and immune suppression.